Mucosal permeability and mast cells as targets for functional gastrointestinal disorders

被引:30
|
作者
Keita, Asa V. [1 ]
Soderholm, Johan D. [1 ,2 ]
机构
[1] Linkoping Univ, Div Surg Orthoped & Oncol, Dept Clin & Expt Med, Linkoping, Sweden
[2] Cty Council Ostergotland, Dept Surg, Linkoping, Sweden
基金
瑞典研究理事会;
关键词
IRRITABLE-BOWEL-SYNDROME; VASOACTIVE INTESTINAL POLYPEPTIDE; DILATED INTERCELLULAR SPACES; EPITHELIAL BARRIER; ABDOMINAL-PAIN; IMMUNE ACTIVATION; REFLUX DISEASE; COLONIC-MUCOSA; STRESS; MICROBIOTA;
D O I
10.1016/j.coph.2018.08.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The intestinal mucosa is constantly exposed to harmful lumina! content, and uptake is closely controlled and regulated by neuro-immune factors. If control is broken, it might lead to ongoing enhanced mucosal permeability, potentially resulting in functional gastrointestinal disorders. The importance of mast cells in the regulation of the mucosal barrier has become obvious, and increased numbers and more activated mast cells have been observed in irritable bowel syndrome, functional dyspepsia and gastroesophageal reflux disease. To target the disturbed mucosal permeability, directly or via mast cells, is therefore currently of major interest. For example, administration of mast cell stabilizers and probiotics have shown promising effects in patients with functional gastrointestinal disorders.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 50 条
  • [21] Mast cells at mucosal frontiers
    Vliagoftis, H
    Befus, AD
    CURRENT MOLECULAR MEDICINE, 2005, 5 (06) : 573 - 589
  • [22] Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis
    Hahn, H. P.
    Hornick, J. L.
    LABORATORY INVESTIGATION, 2007, 87 : 116A - 117A
  • [23] Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis
    Hahn, Hejin P.
    Hornick, Jason L.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (11) : 1669 - 1676
  • [24] Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis
    Hahn, H. P.
    Hornick, J. L.
    MODERN PATHOLOGY, 2007, 20 : 116A - 117A
  • [25] MUCOSAL MAST-CELLS .1. ISOLATION AND FUNCTIONAL-CHARACTERISTICS OF RAT INTESTINAL MAST-CELLS
    BEFUS, AD
    PEARCE, FL
    GAULDIE, J
    HORSEWOOD, P
    BIENENSTOCK, J
    JOURNAL OF IMMUNOLOGY, 1982, 128 (06): : 2475 - 2480
  • [26] From Intestinal Permeability to Dysmotility: The Biobreeding Rat as a Model for Functional Gastrointestinal Disorders
    Vanuytsel, Tim
    Vanormelingen, Christophe
    Vanheel, Hanne
    Masaoka, Tatsuhiro
    Rasoel, Shadea Salim
    Toth, Joran
    Houben, Els
    Verbeke, Kristin
    De Hertogh, Gert
    Vanden Berghe, Pieter
    Tack, Jan
    Farre, Ricard
    PLOS ONE, 2014, 9 (10):
  • [27] Transient Suppression and Functional Modulation of Mucosal Mast Cells for the Treatment of Allergic Disease
    Kurashima, Yosuke
    Takasato, Yoshihiro
    Kiuchi, Masahiro
    Hirahara, Kiyoshi
    Murasaki, Sayuri
    Kunisawa, Jun
    Kubo, Masato
    Nakayama, Toshinori
    Kiyono, Hiroshi
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [28] Rat mucosal mast cell chymase increases paracellular permeability of MDCK-II cells
    Scudamore, CL
    Jepson, MA
    Hirst, BH
    FASEB JOURNAL, 1997, 11 (03): : 1796 - 1796
  • [29] Role of mucosal mast cells in early vascular permeability changes of intestinal DTH reaction in the rat
    Kraneveld, AD
    Muis, T
    Koster, AS
    Nijkamp, FP
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1998, 274 (05): : G832 - G839
  • [30] Gastrointestinal pain in functional bowel disorders: sensory neurons as novel drug targets
    Holzer, P
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2004, 8 (02) : 107 - 123